Key Message
Three randomized controlled trials and 1 non-randomized study were identified regarding the comparative clinical effectiveness of biosimilar versus reference enoxaparin in the prevention or treatment of thrombosis and cardiovascular conditions for adult or pediatric patients.
No relevant literature was identified regarding the clinical effectiveness of switching from reference to biosimilar enoxaparin in the prevention or treatment of thrombosis and cardiovascular conditions for adult or pediatric patients